|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-2-23
|
|
pubmed:abstractText |
Sagopilone (ZK-EPO) is a fully synthetic microtubule-stabilizing agent that has demonstrated high antitumor activity in preclinical models. This first-in-human phase I study aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxic effects (DLTs) of 3-weekly sagopilone treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
633-9
|
|
pubmed:meshHeading |
pubmed-meshheading:19880436-Adult,
pubmed-meshheading:19880436-Aged,
pubmed-meshheading:19880436-Aged, 80 and over,
pubmed-meshheading:19880436-Antineoplastic Agents,
pubmed-meshheading:19880436-Benzothiazoles,
pubmed-meshheading:19880436-Drug Resistance, Neoplasm,
pubmed-meshheading:19880436-Epothilones,
pubmed-meshheading:19880436-Feasibility Studies,
pubmed-meshheading:19880436-Female,
pubmed-meshheading:19880436-Humans,
pubmed-meshheading:19880436-Male,
pubmed-meshheading:19880436-Maximum Tolerated Dose,
pubmed-meshheading:19880436-Middle Aged,
pubmed-meshheading:19880436-Neoplasm Staging,
pubmed-meshheading:19880436-Neoplasms,
pubmed-meshheading:19880436-Salvage Therapy,
pubmed-meshheading:19880436-Survival Rate,
pubmed-meshheading:19880436-Tissue Distribution,
pubmed-meshheading:19880436-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors.
|
|
pubmed:affiliation |
Hammersmith Early Clinical Trials Unit, Charing Cross Hospital, Imperial College London, London, UK. p.schmid@imperial.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I
|
